Donanemab is a prescription medicine used to treat early Alzheimer's disease. It helps reduce harmful protein build-ups called amyloid plaques in the brain and may slow the worsening of memory and thinking problems. It is not a cure, and it does not restore memories or brain functions that have already been lost.
What does donanemab mean, and what type of medicine is it?
Donanemab is a type of medicine called a monoclonal antibody. Monoclonal antibodies are laboratory-made proteins designed to recognize and target specific substances in the body.
In Alzheimer's disease, a protein called beta-amyloid can collect in the brain and form clumps known as amyloid plaques. These plaques are one of the main changes associated with the disease. Another important change involves the build-up of a protein called tau inside brain cells.
Donanemab targets certain forms of beta-amyloid and helps reduce amyloid plaques in the brain. It is therefore described as an anti-amyloid treatment or a disease-modifying treatment. Rather than only managing symptoms, it targets a biological feature involved in Alzheimer's disease.
According to MedlinePlus, donanemab belongs to the monoclonal antibody group and works by reducing amyloid beta plaques that contribute to the progression of Alzheimer's disease.
What is donanemab used for in Alzheimer's disease?
Donanemab is intended for people with early symptomatic Alzheimer's disease. This generally includes two stages:
- Mild cognitive impairment (MCI) due to Alzheimer's disease: A person has noticeable problems with memory or other thinking abilities but can still manage most everyday activities independently.
- Mild Alzheimer's dementia: Memory and thinking difficulties have progressed enough to affect everyday activities, although the person may still manage some tasks independently.
Having memory problems or mild cognitive impairment does not automatically mean someone is eligible. The changes must be linked to Alzheimer's disease, and the presence of amyloid plaques must be confirmed before treatment begins.
In the United States, the Food and Drug Administration (FDA) approved donanemab under the brand name Kisunla for Alzheimer's disease, with treatment intended to begin during the mild cognitive impairment or mild dementia stages. The Alzheimer's Association also explains that treatment was studied in people with early symptomatic Alzheimer's disease and confirmed amyloid build-up. It has not been established as a treatment for advanced Alzheimer's or for people who have amyloid plaques but no clinical symptoms.
How does donanemab help people with Alzheimer's?
Donanemab aims to reduce the amount of amyloid plaque in the brain. By targeting this protein build-up, it may slow the rate at which Alzheimer's-related memory and thinking difficulties worsen.
Clinical trials found that people receiving donanemab experienced slower cognitive and functional decline than people receiving a placebo. Cognitive function includes memory, attention, and thinking. Functional ability refers to everyday activities such as managing personal tasks and following routines.
The difference represents a slowing of disease progression, not a complete stop. A person receiving donanemab may still experience changes in memory, thinking, or daily independence over time.
It is also important to understand what the treatment cannot do:
- It does not cure Alzheimer's disease.
- It does not reliably restore lost memories or reverse existing brain damage.
- It does not prevent every future change in memory or thinking.
- It has not been established as an effective treatment for every type or stage of dementia.
The potential benefit is generally described as slowing the decline rather than making someone return to their previous level of memory or daily functioning.
Who may be suitable for donanemab treatment?
Donanemab is not suitable for everyone with Alzheimer's disease. A specialist usually considers the stage of the condition, evidence of amyloid build-up, brain imaging results, other medical conditions, and the possible risks of treatment.
Confirmation of amyloid plaques
Before treatment, a healthcare professional needs to confirm that amyloid beta pathology is present in the brain. This may involve:
- Amyloid PET scan: A specialised brain scan that can help identify amyloid plaques.
- Cerebrospinal fluid testing: A test using fluid collected from around the brain and spinal cord to assess proteins associated with Alzheimer's disease.
Confirming amyloid build-up is important because not all memory problems or dementia cases are caused by Alzheimer's disease.
Brain MRI before treatment
A brain MRI is generally required before starting donanemab. It helps identify existing brain changes, such as small areas of bleeding, that may affect treatment safety.
The specialist also considers whether the person can attend regular follow-up appointments and brain scans. Monitoring is an essential part of treatment because donanemab can cause changes in the brain that may not produce noticeable symptoms.
Genetic testing and individual risk
Some people carry two copies of a gene variant called ApoE ε4. These individuals, known as ApoE ε4 homozygotes, have a higher risk of developing certain treatment-related brain abnormalities.
The current U.S. prescribing information recommends testing for ApoE ε4 status before treatment to help inform the risk discussion. The healthcare professional should explain the possible meaning of the results before testing takes place.
How is donanemab given?
Donanemab is given through an intravenous (IV) infusion. This means the medicine enters a vein through a small tube, usually in the arm. It is administered by a healthcare professional at an appropriate medical facility.
Under the current U.S. prescribing information, an infusion takes approximately 30 minutes and is given every four weeks. The dose increases gradually over the first three infusions:
- First infusion: 350 mg.
- Second infusion: 700 mg.
- Third infusion: 1,050 mg.
- Fourth infusion and later doses: 1,400 mg.
The dose schedule is based on the current U.S. product label. Treatment arrangements may differ according to local regulatory approval and prescribing information.
According to the DailyMed prescribing information for Kisunla, doctors may also consider stopping treatment when an amyloid PET scan shows that plaque levels have fallen to minimal levels. This means treatment does not necessarily continue indefinitely. The decision depends on imaging results and the treating specialist's assessment.
What monitoring is needed during treatment?
Regular monitoring is important because donanemab can cause amyloid-related imaging abnormalities, commonly called ARIA. These changes may involve swelling or bleeding in the brain.
The current U.S. prescribing information recommends a recent brain MRI before treatment begins, followed by additional MRI scans before the second, third, fourth, and seventh infusions. Further assessment may be needed if symptoms or scan results raise concern.
Monitoring allows the healthcare team to identify ARIA and decide whether treatment can continue, should be paused, or needs to be stopped. The decision depends on the imaging findings, symptoms, and overall clinical situation.
What are the possible side effects and risks of donanemab?
Donanemab can cause side effects ranging from mild problems to serious complications. The most important safety concern is amyloid-related imaging abnormalities (ARIA).
Amyloid-related imaging abnormalities (ARIA)
ARIA refers to changes seen on brain imaging during treatment with certain medicines that target amyloid. It mainly occurs in two forms:
- ARIA-E: Swelling or fluid build-up in or around brain tissue.
- ARIA-H: Small areas of bleeding or blood-related deposits in the brain.
ARIA often does not cause noticeable symptoms. However, some cases can become serious or life-threatening. In rare situations, severe brain bleeding has occurred.
Possible symptoms associated with ARIA include:
- Headache or a new, unusual headache.
- Confusion or changes in mental alertness.
- Dizziness or problems with balance.
- Changes in vision.
- Nausea.
- Difficulty walking or muscle weakness.
- Difficulty speaking or seizures.
These symptoms can have other causes, but they need urgent medical assessment when they occur during donanemab treatment. Sudden weakness, speech difficulty, a seizure, or a serious change in awareness requires immediate medical attention.
Infusion-related reactions
Some people experience a reaction during or shortly after an infusion. Possible symptoms include chills, sweating, nausea, vomiting, headache, skin irritation, chest discomfort, or difficulty breathing.
Medical staff monitor patients during treatment and can respond to these reactions. Depending on their severity, the infusion may need to be slowed, interrupted, or stopped.
Allergic reactions and headache
Headache is among the commonly reported side effects. Donanemab can also cause serious allergic reactions, including swelling of the lips, tongue, or throat, hives, and breathing difficulties. Severe breathing problems or swelling involving the throat require emergency medical care.
Who has a higher risk of ARIA?
People with two copies of the ApoE ε4 gene variant have a higher incidence of ARIA, including symptomatic and serious cases, than people with one or no copies.
Existing brain abnormalities, including certain small areas of bleeding or findings associated with cerebral amyloid angiopathy, may also increase concern about treatment safety.
People taking medicines that affect blood clotting should tell their specialist before treatment. This includes aspirin, antiplatelet medicines, and anticoagulants. These medicines should not be stopped or changed without medical advice.
The U.S. Food and Drug Administration (FDA) highlights ARIA, infusion-related reactions, and allergic reactions among the important safety concerns associated with Kisunla. The FDA also recommends ApoE ε4 testing before treatment to help assess ARIA risk.
Is donanemab a cure for Alzheimer's disease?
No. Donanemab is not a cure for Alzheimer's disease. It is designed to target amyloid plaques and slow the rate of clinical decline in eligible people during the early stages of the condition.
It does not reverse the disease or guarantee that memory and thinking abilities will remain unchanged. A person may continue to need medical care, support with everyday activities, and other parts of an Alzheimer's management plan while receiving treatment.
How is donanemab different from medicines that manage Alzheimer's symptoms?
Some established Alzheimer's medicines, such as donepezil, rivastigmine, and galantamine, are mainly used to help manage symptoms involving memory and thinking. Donanemab belongs to a different treatment group because it targets amyloid plaques, a biological feature of the disease.
This distinction matters when discussing treatment choices. Donanemab is not simply another medicine for improving memory, and it does not replace every other part of Alzheimer's care. A specialist may consider the person's current medicines, health conditions, stage of disease, and treatment goals when planning care.
What should patients and families discuss with a specialist?
Before considering donanemab, patients and family members can discuss several practical questions with the treating neurologist or Alzheimer's specialist:
- Has the diagnosis of Alzheimer's disease been established, and has amyloid build-up been confirmed?
- Is the person's disease at the early stage for which donanemab has been studied and approved?
- What do the brain MRI results show?
- Would ApoE ε4 genetic testing help clarify the person's risk?
- Could current medicines, particularly blood-thinning medicines, affect treatment decisions?
- How often will infusions and monitoring scans be needed?
- What benefits are realistic, and what warning signs should prompt urgent medical attention?
Availability and regulatory approval differ between countries. FDA approval in the United States does not automatically mean that donanemab is approved or routinely available elsewhere. Patients and families should check local treatment availability and prescribing requirements with a qualified specialist.
Overall, donanemab is an important development in Alzheimer's treatment because it targets amyloid plaques rather than only managing symptoms. Its possible benefits need to be weighed against the risk of serious side effects and the need for regular MRI monitoring. Careful assessment by an experienced specialist is essential when deciding whether this treatment is appropriate.